Sparton CEO Chairs Johns Hopkins Alliance for Science and Technology Development Committee
(Jackson, MI) - October 22, 2004 - David W. Hockenbrocht, CEO and President of Sparton Corporation, was recently selected Chairman of the Johns Hopkins Alliance for Science and Technology Development at the Johns Hopkins School of Medicine.
Mr. Hockenbrocht chairs a twelve-member committee charged with evaluating the commercial viability of selected research projects at Johns Hopkins University School of Medicine. The Alliance will then evaluate marketing opportunities and provide assistance with the identification of financing to enable the commercialization of the worthy discoveries.
The Alliance consists of both pharmaceutical and biotech executives; medical device designers and manufacturers; and venture capitalists.
The Alliance's charter is to evaluate research projects within the School of Medicine and determine the commercial strength of each project and assign an Alliance member to champion its development and marketability. The group will also become the university's conduit toward creating awareness among industry leaders and business entrepreneurs. Mr. Hockenbrocht's goal is to have more research projects become market successes or be commercially-ready.
This Alliance among business leaders and university researchers has been made possible under the provisions of the Bayh-Dole Act, which encourages the utilization of inventions produced under federal funding and promotes the participation of universities and small businesses in the development and commercialization process. It also permits exclusive licensing with transfer of an invention to the marketplace.
Sparton Corporation (NYSE:SPA) now in its 104th year, provides design engineering and electronics contract manufacturing services utilizing six manufacturing locations encompassing nearly 800,000 sq. ft. along with several alliance partner facilities. In addition to strong core surface mount technology (SMT) and plated through-hole (PTH), printed circuit board assembly (PCBA) and complete assembly manufacturing capabilities, Sparton offers a complete range of pre-manufacturing, post-manufacturing and engineering services. Pre-manufacturing services include product development, concurrent engineering, design for test (DFT), design for manufacturing (DFM), design for assembly (DFA), printed circuit board design and quick-turn prototyping. Post-manufacturing services range from repair depot, direct ship, distribution management to field support.
Members of the Alliance include:
Mr. David W. Hockenbrocht
Committee Chairman
President & CEO
Sparton Corporation
2400 East Ganson St
Jackson, Michigan 49202
James Campbell, M.D.
Professor, Neurosurgery
Meyer 5-109
600 N. Wolfe Street
Baltimore, MD 21205
C. Thomas Caskey, MD, FACP
Cogene Biotech Ventures, LP
Five Post Oak Park
4400 Post Oak Parkway, Suite 1400
Houston, TX 77027
Michael E. DeMane
President
Medtronic Sofamor Danek
1800 Pyramid Place
Memphis, TN 38132
Mr. Philip Goelet
Red Abbey
Foxleigh Building
2330 West Joppa Road, Suite 300
Lutherville, MD 21093
Leroy E. Hood, MD, PhD
President, Institute for Systems Biology
1441 North 34th Street
Seattle, WA 98103-8904
Mr. Robert S. King
Senior Managing Director
HD Brous & Co., Inc.
New York, NY 10025
Robert D. Mashal, M.D.
Partner
Boston MilleniaPartners
30 Rowes Wharf, Suite 500
Boston, MA 02110
Mr. Richard Newman
Head of Research & Development
Welch Allyn Medical Products
4341 State Street Road
Skaneateles Falls, NY 13153-0220
Stephen N. Oesterle, MD
Senior Vice President for Medicine and Technology
Medtronic, Inc.
710 Medtronic Parkway, NE
Minneapolis, MN 55432-5604
Irving Sherman, MD
Neurosurgeon
2308 Ibis Isle Road
Palm Beach, FL 33480
Craig R. Smith, MD
Chairman, President & CEO
Guilford Pharmaceuticals
6611 Tributary Street
Baltimore, MD 21224
For more information, please contact Rhonda Aldrich, Sparton Corporation at (517) 787- 8600 or visit the Sparton website at http://www.sparton.com/. For information about Johns Hopkins Medicine and its programs, contact Joann Rodgers or Gary Stephenson at (410) 955-6680.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting future results, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.